Term ends Nov 24, 2030 · High confidence
20-year base term ends Nov 24, 2030
Held by MedImmune Limited
Filed Aug 7, 2012 as application 13/511,538 · Granted Jul 15, 2014
Base term, 20 years from filing
Today
2010
2030
Clock starts
Nov 24, 2010
Nov 24, 2010
Term ends
Nov 24, 2030
Nov 24, 2030
Granted
Jul 15, 2014
Jul 15, 2014
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 24, 2010, when application PCT/US2010/058007, the earliest non-provisional in its chain, was filed (this one was filed Aug 7, 2012) | Nov 24, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 24, 2030 | High confidence |
This family
| US 8,779,108 | this patent Nov 2030 | Nov 2030 |
| US 9,493,565 | In force May 2031 | May 2031 |
| US 10,400,039 | In force Nov 2030 | Nov 2030 |
| US 11,518,809 | In force Nov 2030 | Nov 2030 |
| US 12,686,718 | In force Jun 2031 | Jun 2031 |
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 30, 2012 Reel 28874, frame 919 | Hammond, Scott; Mulgrew, Kathleen Ann | MedImmune, LLC | Assignment of Assignor's Interest |
| Aug 30, 2012 Reel 28876, frame 194 | Queva, Christophe; Babcook, John; Foltz, Ian; Sekirov, Laura; Kang, Jaspal Singh | Amgen British Columbia | Assignment of Assignor's Interest |
| Aug 30, 2012 Reel 28874, frame 777 | Morrow, Michelle; Boyle, Melanie; Chodorge, Matthieu; Stewart, Ross A. | MedImmune Limited | Assignment of Assignor's Interest |
| Aug 30, 2012 Reel 28875, frame 103 | Alimzhanov, Marat | AstraZeneca AB | Assignment of Assignor's Interest |
| Oct 4, 2012 Reel 29075, frame 460 | Amgen British Columbia | MedImmune Limited | Assignment of Assignor's Interest |
| Oct 4, 2012 Reel 29075, frame 499 | MedImmune LLC | MedImmune Limited | Assignment of Assignor's Interest |
| Oct 4, 2012 Reel 29075, frame 521 | AstraZeneca AB | MedImmune Limited | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Nov 2030
Term ends Nov 24, 2030. No further fees fall due before then
Citations
166
later US patents cite this one
That is top 5% of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.